Enhanced mGluR5 Availability Marks the Antidepressant Efficacy in Major Depressive Disorder
Research Square
2024
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
The limited efficacy of antidepressants for Major Depressive Disorder (MDD) underscores the need for novel targets. This study explores the role of metabotropic glutamate receptor 5 (mGluR5) in MDD, examining mGluR5 availability changes pre and post-treatment and their link to clinical outcomes. We studied 25 MDD patients and 21 healthy controls, with 13 undergoing eight-week vortioxetine treatment. mGluR5 availability was measured at baseline and follow-up using [18F]FPEB-PET scans, categorizing patients based on response. Results showed a global decrease in mGluR5 availability in MDD patients versus controls at baseline. Post-treatment, remitters exhibited a significant increase in mGluR5 availability in the dorsolateral and ventromedial prefrontal cortex (Cohen’s d = 2.33 and 4.27). These findings underscore mGluR5's key role in MDD pathophysiology and treatment. The post-treatment increase in mGluR5 in key brain areas among remitters suggests its potential as a novel therapeutic target for MDD.
Bibliographic Details
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know